KKR 2026 Conference Call Summary Company Overview - KKR is one of the world's largest alternative asset managers with approximately $744 billion in assets under management (AUM) as of December 31, 2025, covering private equity, real estate, infrastructure, private credit, and liquid strategies [1][3] Strategic Priorities for 2026 - KKR's business model combines asset management, insurance, and strategic holdings, focusing on exceptional investment performance for clients and policyholders [3][4] - Key priorities include: - Integration of the recently acquired Arctos business to leverage synergies [4] - Building a differentiated insurance business by combining sourcing and capital-raising advantages [4] - Investing in people and maintaining KKR's culture as it approaches its 50th anniversary [5] Company Culture - KKR's culture emphasizes long-term employee retention and collaboration, with a unified profit and loss structure that incentivizes teamwork across different business units [9][10] - The firm has implemented an employee ownership program in portfolio companies, resulting in improved engagement and performance metrics [14][16] Macro Environment and Capital Deployment - Despite geopolitical volatility and public policy changes, KKR has not seen a material slowdown in core operating metrics [19][20] - The firm has $120 billion in dry powder for investment, with $6.5 billion allocated to its insurance business, which could translate to over $65 billion in fee-paying AUM when fully deployed [22][23] Private Credit Insights - KKR's private credit AUM is approximately $135 billion, with $85 billion from asset-based finance and $40 billion from direct lending [26][28] - The firm sees opportunities in the private credit space, particularly in asset-based finance, while maintaining a cautious approach to direct lending [29][30] Software Portfolio - KKR's software exposure is about 7% of AUM, with a focus on identifying winners and losers in the evolving software landscape [31][41] - The firm is a significant user of technology and anticipates continued demand for enterprise-wide software [40] Fundraising Performance - KKR raised a record $129 billion in 2025, with a diversified fundraising approach that includes institutional, insurance, and private wealth channels [45][46] - The firm aims to build long-term products and vehicles in private wealth, with recent capital raises showing a 20% year-over-year increase [49][50] Strategic Holdings - KKR's strategic holdings aim to generate compounding cash flow, with plans to increase operating earnings from $350 million in 2026 to over $1.1 billion by 2030 [67][68] - The diversified portfolio of approximately 20 businesses is expected to contribute to achieving these targets [68][70] Acquisition of Arctos - The acquisition of Arctos is seen as a strategic move to lead in sports team and league investing, as well as to provide liquidity solutions to alternative asset managers [61][64] - KKR aims to build a $100 billion platform through this acquisition, leveraging Arctos's expertise and KKR's capital access [66] Conclusion - KKR feels well-positioned to navigate current market volatility and execute its business model effectively, with a strong team and a clear vision for future growth [73]

Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Development of deucrictibant for treating Hereditary Angioedema (HAE) Recent Progress and Priorities - Pharvaris is preparing to file its first drug for acute treatment based on strong data from December 2025 - Ongoing prophy trial expected to have top-line readout in Q3 2026 - Enrollment in a pivotal trial for acquired angioedema is ongoing - Preparing for commercial launch and organizational ramp-up [4][11][19] Clinical Data Highlights - **RAPIDe-3 Trial Results**: - Primary endpoint (PGIC) achieved with deucrictibant relieving symptoms in approximately 1.28 hours compared to over 12 hours for placebo - New endpoint "End of Progression" showed patients stopped feeling worse in about 17.5 minutes - Complete symptom resolution achieved in less than 12 hours, outperforming standard care [8][9][10] Regulatory and Launch Preparations - NDA submission planned for the first half of 2026, with preparations on track - Pre-NDA meeting has already occurred, and the company is working towards a complete filing [11][13][17] Market Position and Strategy - The company anticipates a standard review from regulators, aiming for a potential launch in the first half of 2027 [17] - Emphasis on building visibility in the healthcare community through the "Deflate HAE" campaign to raise disease awareness [19][22] - The campaign aims to address the unmet need for effective treatments in the HAE patient community [22][24] Competitive Landscape - The oral on-demand treatment segment is expected to dominate, with a strong preference for oral therapies over injectables due to convenience [34][44] - The company believes that the profile of deucrictibant positions it favorably against existing treatments, particularly in terms of speed and efficacy [36][38] - There is a significant opportunity to switch patients from existing treatments to deucrictibant, especially as the oral segment grows [90][91] Prophylactic Opportunity - The CHAPTER-3 pivotal trial is progressing on track, with data expected in Q3 2026 [65] - The extended-release formulation is being developed alongside the immediate-release formulation, with distinct pharmacokinetic profiles [68][71] - The company aims for a broader label that includes normal C1 patients, addressing additional unmet medical needs [54][81] Financial Position - Cash balance reported at EUR 380 million as of Q3 2026, with a runway projected to the first half of 2027 [123] Conclusion - Pharvaris is strategically positioned to capitalize on the growing demand for oral therapies in the HAE market, with a strong focus on clinical data, regulatory preparations, and market awareness campaigns to support its upcoming product launches.

AIRO Group Conference Call Summary Company Overview - **Company**: AIRO Group (NasdaqGM:AIRO) - **Industry**: Aerospace, Defense, and Mobility Core Earnings Drivers - **Primary Driver**: Drones, particularly in military applications, with a strong demand for replenishment of conventional systems and growth in military drone usage [4][5] - **Secondary Driver**: Large cargo drones, focusing on cargo aspects rather than eVTOL [5][6] - **Current Orders**: Approximately $190 million in orders from NATO customers, expected to be delivered through 2026 [6] Competitive Advantages (Moats) - **Unique Product**: RQ-35 drone, battle-proven with thousands in operation in Ukraine, capable of 500+ missions and effective in GPS-contested environments [7][8] - **AI Integration**: Onboard AI for autonomy, enabling target and pattern recognition, applicable in military and commercial sectors [8] - **U.S. Production Facility**: New facility in North Phoenix allows for significant aircraft production for U.S. military, meeting domestic manufacturing requirements [9] Technology Focus - **Communication and Avionics**: Strong capabilities in spread spectrum radios and in-house avionics manufacturing, with over 16,000 installations in manned aircraft [10][12] - **R&D Strategy**: Focus on core divisions (drones and avionics), with emphasis on production scalability and product improvement [15][59] Synergies and Training - **Product Line Synergy**: Shared flight control technologies and AI enablement across drone products, reducing development costs [19] - **Training Opportunities**: Growing need for drone pilot training, with embedded troops in Ukraine training military personnel [20][21] Long-term Growth Outlook - **Drones as Growth Segment**: Expected to be the largest growth area, with training and avionics providing predictable revenue [27][75] - **Sensor Development**: Manufacturing own GNSS sensors to meet high-quality navigation needs in the drone market [28] Government Programs and Market Dynamics - **Drone Dominance Program**: U.S. Department of War's recognition of the need for effective drone systems, moving beyond traditional manned systems [34] - **ISR Capabilities**: Increased demand for intelligence, surveillance, and reconnaissance platforms, particularly in conflict zones [37] International Market Focus - **NATO and Global Markets**: Strong demand from NATO countries involved in the Ukrainian conflict, with expansion plans in the Middle East, Africa, and Asia [46][47] Certification and Regulatory Strategy - **Canadian Certification**: Working with Transport Canada for airframe certification, which will facilitate reciprocal certification in the U.S. [54][55] Cost Management and Investment Strategy - **Focus on Cost Control**: Emphasis on just-in-time inventory and disciplined spending to maintain margins [65][66] - **Investment in Training**: Bidding for higher-value contracts with the Department of Defense [61] Key Takeaways for Investors - **Battlefield-Proven Technology**: AIRO's drones are effective in current conflicts, positioning the company well for future U.S. government procurements [81] - **Management Team**: Experienced leadership with a strong track record in the industry [82] - **Civilian Applications**: Potential for significant civilian applications of drone technology as military conflicts evolve [83]

Cathay Pacific Airways (SEHK:00293) H2 2025 Earnings call March 11, 2026 09:00 AM ET Company ParticipantsPerry Yeung - DirectorRonald Lam - CEOPerry YeungThank you very much. This is Perry from UBS. Congratulations for the first strong result for three years in a row. I got two questions. First related to your passenger capacity. You've been saying, we are going to grow 10% this year. In terms of the fleet, we are probably growing at 4% in terms of your passenger aircraft. I'm curious in terms of the growth ...

Cathay Pacific Airways (SEHK:00293) H2 2025 Earnings call March 11, 2026 09:00 AM ET Company ParticipantsPerry Yeung - DirectorRonald Lam - CEOPerry YeungThank you very much. This is Perry from UBS. Congratulations for the first strong result for three years in a row. I got two questions. First related to your passenger capacity. You've been saying, "We are going to grow 10% this year." In terms of the fleet, we are probably growing at 4% in terms of your passenger aircraft. I'm curious in terms of the grow ...

Summary of Alphatec FY Conference Call (March 11, 2026) Company Overview - **Company**: Alphatec (NasdaqGS: ATEC) - **Industry**: Spine Surgery and Medical Devices Key Points Market Position and Growth Opportunities - Alphatec has made significant progress in the past year, addressing previous concerns regarding capital deployment, financing, and EBITDA, ending the year with strong cash flows and EBITDA [3][4] - The spine surgery market presents substantial growth opportunities, with Alphatec positioned as a smaller player amidst market share shifts among larger competitors [4][12] - The company believes that improving surgical outcomes through better technology will drive market share growth, as high revision rates in spine surgery indicate room for improvement [9][10] Surgeon Adoption and Utilization Metrics - Surgeon adoption rates have been around 20% over the last eight quarters, with a notable 23% in Q4 [21] - New surgeon users tend to drive mid-double-digit volume growth in subsequent years, indicating a long-term utilization improvement [21] - The average selling price (ASP) for cases is expected to grow at a low single-digit rate, reflecting increased complexity in surgeries as surgeons gain experience with Alphatec's products [22][27] Financial Performance and Cash Flow Management - The company achieved a 41% drop-through to reach approximately 12% adjusted EBITDA last year, with a guidance of 32% drop-through for the current year [64][65] - Effective management of inventory and asset deployment is crucial for supporting growth, with a target of 75 cents on the growth dollar basis [65][66] Competitive Landscape and Rep Dynamics - The competitive environment has been influenced by major players like Stryker and J&J making strategic moves, which has lowered the friction for rep transitions and increased the availability of talent [32][41][45] - The selection of new reps reflects the overall market share dynamics, with no significant over-indexing from any particular competitor [39] Technological Innovations - Alphatec is investing in enabling technologies, such as the Valence robot, which aims to enhance surgical precision and efficiency, particularly in complex procedures [50][58] - The Valence robot is positioned at a competitive price point, making it accessible for both large academic settings and community hospitals [58] Conclusion - Alphatec is confident in its growth trajectory, driven by improved surgeon adoption, innovative technologies, and effective cash flow management strategies. The company is well-positioned to capitalize on the evolving landscape of the spine surgery market [8][12][66]

Shake Shack Conference Call Summary Company Overview - Shake Shack operates over 400 domestic locations and more than 230 international locations, positioning itself as a modern roadside burger stand with significant growth potential driven by global unit development, digital innovation, and menu enhancements [1][3] Key Points Top Line Performance - Shake Shack reported strong performance in 2025 and a robust start in 2026, with resilience noted despite challenging weather conditions [3] - Operational improvements are cited as the foundational driver of sales growth, emphasizing the importance of efficient operations in enhancing customer experience and lifetime value [4][8] Operational Improvements - The company has focused on enhancing operational capabilities, which has positively impacted margins and sales growth [3][4] - Specific improvements include better packaging and ingredient quality, as well as increased cook times for fries to reduce customer complaints from 30% to less than 10% [6][7] Marketing Strategy - Shake Shack is shifting its marketing approach to include top-of-funnel media, moving away from solely low-funnel conversion tactics [9] - The "one-three-five" promotion in the app has driven a 50% increase in app traffic and a 900 basis points increase in customer frequency since its launch [10][11] Menu Innovation - Shake Shack has a history of culinary innovation and plans to continue launching limited-time offers (LTOs) and new menu items, with a focus on big protein and sandwich innovations [14][16] - The company aims to balance premium product offerings to encourage customers to trade up, thereby improving the overall value equation [19][20] Pricing Strategy - The company has maintained a disciplined pricing strategy, with net pricing increases of only 3% last year, despite significant beef inflation [21] - Future pricing strategies aim for a target of around 2% net pricing increase, focusing on maintaining value while driving traffic [24][25] Development Opportunities - Shake Shack has ambitious plans for expansion, targeting 1,500+ locations, with confidence in its ability to succeed in diverse markets [58][63] - The company is developing multiple restaurant formats to optimize real estate opportunities and improve operational efficiency [59][60] Macro Environment - Shake Shack has shown resilience in a challenging macroeconomic environment, with a focus on diversifying its footprint beyond high-income areas [37][39] - The company believes it can create value in lower-income markets by emphasizing quality and customer experience [40][41] Margin Management - The company has achieved margin growth through labor efficiency and improved procurement strategies, including competitive sourcing of ingredients [71][72] - Future initiatives will focus on enhancing distribution and logistics to further drive down costs [74] Leadership and Future Outlook - Shake Shack is in the process of hiring a new CFO to complete its executive team, aiming for a candidate with relevant experience in public companies and the restaurant industry [76] Additional Insights - Shake Shack's marketing investments are closely tied to revenue growth, with a focus on ensuring that every dollar spent delivers a return [29][30] - The company is committed to maintaining high-quality standards while managing costs, ensuring that any new suppliers meet their quality thresholds [72] This summary encapsulates the key insights from Shake Shack's conference call, highlighting the company's operational strategies, marketing initiatives, and growth outlook in a competitive landscape.

Financial Data and Key Metrics Changes - The company reported a 6% decline in net sales, leading to a significant margin drop of 390 basis points in the quarter, with a snack segment margin of only 7% [14][15][16] - The company anticipates a slight improvement in margins in Q3, but expects a more substantial recovery in Q4 due to stabilization in bakery performance and lower marketing expenses [15][39] Business Line Data and Key Metrics Changes - The snacks segment is focusing on three key areas: Goldfish, Fresh Bakery, and Salty snacks, with Goldfish showing momentum but facing challenges in Fresh Bakery execution [10][11] - The company expects snacks to decline about 4% in the second half of the fiscal year, with a slight improvement anticipated in Q4 [40][41] Market Data and Key Metrics Changes - The competitive landscape in the salty snacks category has intensified, prompting the company to adjust its pricing strategy and promotional activities [12][30] - The company is experiencing mixed results in distribution, with gains in Goldfish but neutral performance in chips due to competitive pressures [76][77] Company Strategy and Development Direction - The company is focusing on improving competitiveness through pricing adjustments, promotional activities, and innovation in its product portfolio [12][32] - There is a strong emphasis on capital allocation towards debt reduction and maintaining cash flow, with no plans for share buybacks in the near term [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges in the operating environment, particularly in the snacks segment, but remains optimistic about the potential for growth in key brands like Goldfish and Rao's [61][90] - The company is committed to stabilizing its top line and improving margins through operational efficiencies and cost reductions [88] Other Important Information - The company is investing in its Goldfish manufacturing capacity, but has faced challenges in volume growth, impacting margins [67] - The introduction of Campbell's Condensed Sauces is expected to complement existing products and cater to evolving consumer cooking behaviors [91] Q&A Session Summary Question: Insights on snacks performance and competitive strategies - Management highlighted the need for surgical promotional strategies in the salty snacks category to remain competitive against larger rivals [30][32] Question: Fresh bakery execution challenges - Management noted that manufacturing and distribution disruptions, exacerbated by winter storms, have impacted fresh bakery performance, but improvements are being seen [19][20] Question: Capital allocation priorities - The company is prioritizing debt reduction and cash flow preservation, with no immediate plans to increase dividends or engage in share buybacks [22][23] Question: Pricing strategies in meals and beverages - Management confirmed that there will still be positive net price realization in the second half, although it may not be as significant as in previous periods [95] Question: Future growth expectations in snacks - Management expressed confidence in the potential for growth in Goldfish and other key brands, despite current challenges in the snacks segment [61][64]

Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, focuses on precision oncology, specifically developing small molecule TERN-701 for chronic myeloid leukemia (CML) [3][4] - TERN-701 has shown unprecedented efficacy, demonstrating 2-3 times the efficacy compared to other agents with a differentiated safety profile [3][12] Industry Context - The chronic myeloid leukemia (CML) market has a significant unmet need, particularly in patients who do not achieve major molecular response (MMR) [5][4] - Current treatments, including imatinib and asciminib, have limitations, with over 75% of patients not responding adequately to the best available therapies [5][6] Key Findings from Recent Data - TERN-701 achieved a 75% MMR in patients at doses of 320 mg and above, with deep molecular response rates exceeding 30% [11][12] - The safety profile of TERN-701 is favorable, with low rates of cytopenias and no significant adverse events compared to asciminib [12][13] - TERN-701 has shown efficacy in asciminib-refractory patients, a critical indicator of its potential superiority [15][27] Competitive Landscape - Asciminib has gained approximately 25% market share in the frontline setting, with expectations to reach 50% [6][7] - TERN-701 is positioned as a potential best-in-disease drug due to its efficacy, safety, and lack of food effect, which is crucial for patient adherence [27][40] - The company anticipates that TERN-701 will outperform asciminib in frontline settings, where newly diagnosed patients are generally easier to treat [32][40] Development Plans - Terns Pharmaceuticals plans to conduct a registrational study for TERN-701 in a second-line plus population, with a control arm of a physician's choice 2GTKI [84][86] - A frontline study is also planned, potentially comparing TERN-701 against imatinib or asciminib [86][88] - The company aims to finalize dose selection and engage with the FDA for guidance on study design by mid-2026 [43][82] Financial Position - Terns Pharmaceuticals has secured funding that positions it well for commercialization and launch of TERN-701 in the second-line plus setting [93][94] Additional Insights - The absence of a food effect with TERN-701 is a significant advantage, as many patients struggle with dietary restrictions associated with other therapies [49][55] - The company is exploring a mutation-specific cohort in its studies to address patients with specific genetic mutations, such as T315I [66][72] Conclusion - Terns Pharmaceuticals is poised to make a significant impact in the CML treatment landscape with TERN-701, addressing critical unmet needs and positioning itself against established therapies like asciminib and imatinib. The upcoming studies and FDA interactions will be pivotal in shaping the future of TERN-701 in the market [40][93]

Financial Data and Key Metrics Changes - Total revenue for 2025 increased by 13.5% year-over-year, reaching $597 million, with Q4 revenue at $159 million, a 17% increase over Q4 2024 [3][8][12] - Adjusted net income rose by 69% year-over-year, reaching $140 million for the full year, with Q4 adjusted net income at a record $26 million, up 27% from the previous year [3][10][15] - GAAP net income increased by 175% to $38 million in Q4, driven by higher revenues and lower expenses [11] Business Line Data and Key Metrics Changes - Originations for 2025 increased by 12% to $899 million, contributing to a 16% increase in ending receivables to $493 million [12][14] - In Q4, originations increased by 8% year-over-year to $230 million, with ending receivables growing by 16% [8][12] - The revenue yield remained stable at 130% for Q4, with an average yield of 133% for the full year, up from 131% in 2024 [8][12] Market Data and Key Metrics Changes - The auto-approval rate in Q4 was 79%, facilitating more customer approvals without human interaction [3] - Higher delinquencies were noted in summer vintages, but the company maintained strong unit economics [3][9] Company Strategy and Development Direction - The company plans to release Model 6.1 in the first half of 2026 to boost originations and reduce risk, with Model 7.0 expected in Q3 2026 [4][5] - The Lola system, designed to leverage AI tools, is in the QA phase and expected to migrate in Q3 2026, aimed at improving efficiency and product development [5][6] - A new line of credit product is set to launch in summer 2026, expanding geographic reach and providing fair credit access [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in both revenue and earnings for 2026, supported by improving vintage metrics and strong recovery indicators [4][19] - The impact of inflation and gas prices on customer repayment is being closely monitored, with a focus on targeting lower-risk segments [25][49] - The company is optimistic about the upcoming tax refund season, which is expected to positively influence credit performance [55] Other Important Information - The company repurchased 515,000 shares of Class A common stock for $5 million during Q4 [12] - Total funding capacity stood at $618 million at the end of the quarter, with $204 million in unused debt capacity [11][12] Q&A Session Summary Question: Impact of geopolitical events on loss emergence - Management noted that early indicators of repayment issues can be observed within 28 to 42 days of loan origination, with a focus on consumer sentiment [17][18] Question: Credit tightening and loss guidance for 2026 - Management indicated that while there was some tightening in response to summer vintages, they are confident in their risk-based pricing model and expect stable performance moving forward [26][28] Question: Learnings from higher losses in summer vintages - Management stated that no specific type of loan or risk tier was identified as the sole reason for higher losses, emphasizing the importance of monitoring consumer sentiment [33][35] Question: Capital allocation and free cash flow - Management discussed the potential for share buybacks, M&A opportunities, and investments in technology systems as part of their capital allocation strategy [42][44]